MedTrace Logo

Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma

NCT02367859 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2024-01-30

Study results available
· View outcomes & findings →

Summary

This pilot clinical trial studies dabrafenib and trametinib in treating patients with ameloblastoma and a specific mutation (change) in the BRAF gene. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Ameloblastoma
  • BRAF Gene Mutation

Interventions

DRUG

Dabrafenib

Given PO

DRUG

Trametinib

Given PO

Sponsors & Collaborators

Principal Investigators

  • Alexander Colevas · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-17
Primary Completion
2018-11-05
Completion
2019-06-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02367859 on ClinicalTrials.gov